ArticleOncology letters2026
Boost delivery in hypofractionated breast cancer radiotherapy: A registry-based analysis of treatment patterns and survival.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypofractionated radiotherapy (RT) has become standard in breast cancer treatment; however, the factors guiding boost application and its impact on survival remain uncertain. In the present study, predictors of boost application and its association with survival were analyzed. A registry-based analysis of n=3,411 patients with breast cancer treated with hypofractionated RT, including 40 post-mastectomy cases, was conducted; n=1,366 patients received a boost. Predictors of boost administration were assessed using uni- and multivariate logistic regression, and overall survival (OS) was examined using Cox hazards models, including subgroup analyses stratified by boost RT, with missing data addressed using complete-case and multiple imputation approaches. The median age was 62 years (interquartile range, 54-70 years). Younger age [odds ratio (OR), 0.96 per year; 95% CI, 0.95-0.97], higher T-stage (T2; OR, 2.54; 95% CI, 1.86-3.48), positive HER2 status (OR, 1.85; 95% CI, 1.31-2.61) and RT target volume (whole-breast irradiation) predicted boost administration. Higher T-stage [T2: hazard ratio (HR), 1.72; 95% CI, 1.04-2.84; T3+: HR, 4.26; 95% CI, 1.55-11.7] and older age (HR, 1.06 per year; 95% CI, 1.04-1.09) were associated with worse OS, while positive progesterone receptor (PR) status predicted improved OS (HR, 0.46; 95% CI, 0.23-0.90). Boost administration exhibited no significant impact (HR, 0.98; 95% CI, 0.60-1.58). In this registry-based cohort, younger age, higher T-stage, positive HER2 status and RT target region independently predicted boost administration. While higher T-stage, older age and PR negativity were associated with worse OS, boost administration itself had no significant impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.